In addition, using our breast cancer MCF10A-derived BMP2-driven early transformation model or primary non-tumoral tissues from BRCA-mutated carriers, we established that the ENI10 is a powerful tool to identify very early transformation processes, further confirmed in the context of melanoma in which CD10 has been associated with aggressiveness and treatment escape (58). The gene discussed is BMP2; the disease is melanoma.